menu
    • menu
    [{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Cerecor","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"AEVI-002","moa":"LIGHT","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Cerecor","highestDevelopmentStatusID":"6","companyTruncated":"Kyowa Kirin \/ Cerecor"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kyowa Kirin

                            Japan arrow
                            EPS
                            Not Confirmed

                            Kyowa Kirin

                            Japan arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AEVI-002

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Cerecor

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Cerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002

                            Details : CERC-002 is a first-in-class anti-LIGHT monoclonal antibody. LIGHT is homologous to lymphotoxin and exhibits an inducible expression. It competes with the HSV glycoprotein D for binding to the herpesvirus entry mediator, a receptor expressed on T lymphoc...

                            Product Name : CERC-002

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            March 29, 2021

                            Lead Product(s) : AEVI-002

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Cerecor

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth